Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation

被引:40
作者
Cushman, M
机构
[1] Univ Vermont, Dept Med, Burlington, VT 05446 USA
[2] Univ Vermont, Dept Pathol, Burlington, VT 05446 USA
关键词
D O I
10.1016/S0002-9149(02)02419-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The lipid-lowering effects of hormone replacement therapy (HRT) can only partly explain the possible decrease in cardiovascular risk noted in observational studies with hormone use in postmenopausal women. Other possible mechanisms have been explored, including the role of inflammation and coagulation factors. There is mounting evidence that inflammation plays a critical role in the pathogenesis of atherosclerosis, and it has been demonstrated that higher levels of circulating proinflammatory factors are predictive of cardiovascular events. Thus, the effects of hormones and other agents on these factors are of considerable interest. In this article, the effects of various types of HRT and estrogen receptor modulators on inflammation and coagulation markers are reviewed, and their potential impact on clinical outcomes is considered. (C) 2002 by Excerpta Medica, Inc.
引用
收藏
页码:7F / 10F
页数:4
相关论文
共 30 条
[1]   Complement and atherogenesis - Binding of CRP to degraded, nonoxidized LDL enhances complement activation [J].
Bhakdi, S ;
Torzewski, M ;
Klouche, M ;
Hemmes, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (10) :2348-2354
[2]  
Biasucci L M, 2001, Ital Heart J, V2, P164
[3]   C-REACTIVE PROTEIN INDUCES HUMAN PERIPHERAL-BLOOD MONOCYTES TO SYNTHESIZE TISSUE FACTOR [J].
CERMAK, J ;
KEY, NS ;
BACH, RR ;
BALLA, J ;
JACOB, HS ;
VERCELLOTTI, GM .
BLOOD, 1993, 82 (02) :513-520
[4]   Hormone replacement therapy, inflammation, and hemostasis in elderly women [J].
Cushman, M ;
Meilahn, EN ;
Psaty, BM ;
Kuller, LH ;
Dobs, AS ;
Tracy, RP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (04) :893-899
[5]   Effect of postmenopausal hormones on inflammation-sensitive proteins - The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study [J].
Cushman, M ;
Legault, C ;
Barrett-Connor, E ;
Stefanick, ML ;
Kessler, C ;
Judd, HL ;
Sakkinen, PA ;
Tracy, RP .
CIRCULATION, 1999, 100 (07) :717-722
[6]   Tamoxifen and cardiac risk factors in healthy women - Suggestion of an anti-inflammatory effect [J].
Cushman, M ;
Costantino, JP ;
Tracy, RP ;
Song, K ;
Buckley, L ;
Roberts, JD ;
Krag, DN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (02) :255-261
[7]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388
[8]   Hormones to prevent coronary disease in women: When are observational studies adequate evidence? [J].
Grady, D ;
Hulley, SB .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (12) :999-1001
[9]   Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women [J].
Hulley, S ;
Grady, D ;
Bush, T ;
Furberg, C ;
Herrington, D ;
Riggs, B ;
Vittinghoff, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (07) :605-613
[10]   C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men -: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992 [J].
Koenig, W ;
Sund, M ;
Fröhlich, M ;
Fischer, HG ;
Löwel, H ;
Döring, A ;
Hutchinson, WL ;
Pepys, MB .
CIRCULATION, 1999, 99 (02) :237-242